Logo

AstraZeneca Reports First Patient Vaccinating in P-II/III D7220C00001 Trial for AZD2816 to Prevent COVID-19

Share this

AstraZeneca Reports First Patient Vaccinating in P-II/III D7220C00001 Trial for AZD2816 to Prevent COVID-19

Shots:

  • The 1st patient has been vaccinated in a P- II/III D7220C00001 trial assessing the safety & immunogenicity of AZD2816 in 2-250 adults aged >18yrs. with COVID-19 in both previously vaccinated & unvaccinated adults
  • AZD2816 will be given to patients who have previously fully vaccinated with 2 doses of Vaxzevria at least 3mos. after the last injection. In unvaccinated patients- AZD2816 will give in 2 doses 4-12wks. apart- or as a 2nd dose following the 1st dose of Vaxzevria @4wks. apart
  • The initial data of the study is expected in 2021. The data will be submitted to regulators for assessment as a next-generation booster vaccine and through an expedited regulatory pathway

Ref: AstraZeneca | Image: Business Standard

 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions